Tag Archives: Mycamine®

Sandoz Expands Hospital Offering and Anti-Infectives Portfolio with Mycamine® Brand Rights Acquisition

(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has successfully acquired the worldwide brand rights for the systemic antifungal agent Mycamine® (micafungin sodium) from Astellas. This acquisition bolsters Sandoz’s position in the global hospital sector and enhances … Read the full press release

Sandoz acquires Mycamine, reinforcing its anti-infectives portfolio

(IN BRIEF) Sandoz, a global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas. This acquisition will reinforce Sandoz’s hospital … Read the full press release

Sandoz adquiere Mycamine, reforzando su cartera de antiinfecciosos

(NOTICIA EN BREVE) Sandoz, líder mundial en medicamentos sin patente (genéricos y biosimilares), ha firmado un acuerdo para adquirir los derechos de producto a nivel mundial del agente antifúngico sistémico líder Mycamine® (micafungina sódica, Funguard® en Japón) de Astellas. Esta … Read the full press release